HUMA Insider Trading Activity and SEC Form 4 Filings
HUMA insider trading summary
Over the past 12 months, insiders at Humacyte, Inc. (HUMA) reported 5 open-market purchases worth $90K by 3 insiders and 2 sales worth $82K by 2 insiders on SEC Form 4. Net insider buying was $8K.
Latest HUMA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Keith Anthony Jones | Insider | Buy | $6K (10,000 @ $0.56) |
| Aug 20, 2026 | Keith Anthony Jones | Insider | Buy | $7K (10,000 @ $0.69) |
| Aug 17, 2026 | Keith Anthony Jones | Insider | Buy | $18K (30,000 @ $0.59) |
| May 19, 2026 | Kathleen Sebelius | Insider | Buy | $50K (56,818 @ $0.88) |
| May 18, 2026 | Shamik J Parikh | Chief Medical Officer | Sell | $41K (45,887 @ $0.90) |
| May 18, 2026 | Dale A. Sander | CFO and Chief Corp. Dev. Off | Sell | $41K (45,887 @ $0.90) |
| May 18, 2026 | Michael T. Constantino | Insider | Buy | $10K (11,000 @ $0.89) |
| Aug 20, 2025 | Laura E Niklason | President, CEO and Director | Sell | $935K (591,685 @ $1.58) |
| Aug 20, 2025 | Brady W Dougan | Director | Sell | $935K (591,685 @ $1.58) |
| Aug 19, 2025 | Brady W Dougan | Director | Sell | $1.8M (1,100,000 @ $1.63) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.